Nutriband Inc. (NASDAQ: NTRB) has expanded its intellectual property portfolio for its innovative AVERSA™ transdermal pharmaceutical platform, receiving a U.S. trademark and additional international patent protections. The company's strategic focus on developing abuse-deterrent drug delivery systems could potentially address a substantial market need in the pharmaceutical industry.
The newly granted U.S. trademark covers pharmaceutical and product research and development, while a patent in Macao brings the total number of countries providing intellectual property protection to 46. The AVERSA™ platform is specifically designed to minimize drug abuse, diversion, and accidental exposure for potent medications like fentanyl.
With the potential U.S. sales opportunity for its fentanyl patch estimated between $80 million and $200 million, Nutriband is positioning itself as a significant player in the abuse-deterrent pharmaceutical market. The company has also expanded its brand visibility through a strategic partnership with Charlotte FC, further enhancing its market presence.
These intellectual property advancements represent a critical strategic move for Nutriband, potentially offering long-term market protection and establishing a competitive advantage in the development of safer pharmaceutical delivery systems. The company's focus on reducing medication misuse could have significant implications for public health and pharmaceutical innovation.
